In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teijin Pharma Limited.

https://www.teijin-pharma.com/

Latest From Teijin Pharma Limited.

Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs

Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.

United Kingdom Health Technology Assessment

Roche's SERD Setback Means Menarini Retains An Edge

Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.

Cancer Clinical Trials

Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf

AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.

Deal Watch Business Strategies

Sun Signs $485m Settlement Deal To Close Out Ranbaxy Antitrust Case

India’s Sun Pharma is set to hand over almost half-a-billion dollars to resolve claims that its Ranbaxy unit schemed to delay the launch of generic versions of three popular prescription drugs. The firm has denied all allegations as part of the deal, which must be signed off by a US district court.

Legal Issues Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Medical Devices
    • Rehabilitation Equipment and Devices
  • Other Names / Subsidiaries
    • MedTech Heart
UsernamePublicRestriction

Register